Blog Post

Price discrimination in the pharmaceutical sector: new decision, but plaintiffs face same challenges

Blog Post

Outlook for 2015: Antitrust Litigation in the Pharma Industry - More Than Just Actavis Progeny

Blog Post

Federal Circuit Revives Certain Sham Petitioning Antitrust Counterclaims in Tyco-Mutual ANDA Litigation

Blog Post

Defining "Payments": The First Post-Actavis Battleground in Pharmaceutical Reverse Payments

Blog Post

DOJ and FTC to Shine Spotlight on Analysis of Conditional Pricing Practices Under the Antitrust Laws

Blog Post

CT AG Leads Charge to Increase Transparency of Hospital-Physician Acquisitions and Facility Fees

Blog Post

Actelion Settles REMS Dispute with Generic Drug Manufacturers

Last week Actelion settled a lawsuit against two generic drug manufacturers regarding whether Actelion is required to supply those generic firms with samples of its drug Tracleer for use in ...

Blog Post

NY Attorney General Forges New Ground in Scrutiny of Pharmaceutical Agreements With First-Filer Exclusivity No-Challenge Settlement

The New York Attorney General's (NYAG) office has announced that it has reached a settlement with two generic drug manufacturers regarding allegations that an agreement between the firms...

Blog Post

Federal Judge Limits Antitrust Scrutiny of Pharmaceutical Reverse Payments to Settlements Involving Monetary Transfers

Recently, a federal judge in the U.S. District Court for the District of New Jersey held that only patent settlements involving a reverse monetary payment will be subject to antitrust...

Blog Post

FTC finalizes rule extending reporting requirements for pharmaceutical patent transfers

Blog Post

Federal judge allows discovery to proceed in REMS duty to deal dispute